Melanoma is the fifth most common cancer in the U.S., and often recurs as multiple small tumors of the extremities. While these small tumors, called “in-transit” disease, can be treated through chemotherapy given directly to the affected limb, the standard for this focused or “regional” treatment has not been improved upon for more than 50 years. Preclinical research at Roswell Park Comprehensive Cancer Center demonstrates that the new anticancer drug CBL0137 is more effective than standard chemotherapy at killing melanoma tumor cells and was well tolerated in laboratory models. The study has been published online ahead of print in Cancer Research, a journal of the American Association for Cancer Research.